Pharmaceutical Executive
Obtaining patient perspectives during open-label extension trials.
Ross Weaver
Advertisement
Articles by Ross Weaver
Pharmaceutical Executive
Getting patient insights before launch is more feasible than you might think.
Advertisement
Latest Updated Articles
The Feasibility of Patient Insights Before LaunchJuly 16th 2019
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request
2
Johnson & Johnson’s Experience Navigating The Commissioner’s National Priority Voucher Program
3
How AI Is Transforming Drug Labeling
4
FDA’s Shift Signals a New Era for Data-Driven Drug Development
5